Image source: Thermo Fisher Scientific

Development of a highly sensitive analytical workflow

Collaboration for infectious disease diagnosis and patient monitoring

Thermo Fisher Scientific and NanoPin Technologies, Inc. have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows.

Through the detection of disease-related antigens directly from patient blood samples, NanoPin's unique diagnostic platform using Thermo Fisher's advanced LC-MS technology will lead to the development of sensitive clinical assays for infectious disease. This will enable healthcare providers to reduce time to results, determine infection stage and monitor patient response to prescribed treatment. The quantified information gleaned from the combined technology will support clinical decision-making and the provision of personalized patient care unique to their disease state.

The current diagnostic solutions available for the detection and monitoring of infectious disease are not sufficient because they limit patient outcomes and the global management of such ailments

Thomas Tombler

"Time is critical when it comes to the diagnosis and treatment of patients suffering from infectious disease, and current methods do not facilitate prompt diagnosis and rapid evaluation of treatment response," said Bradley Hart, senior director, clinical research, chromatography and mass spectrometry, Thermo Fisher Scientific.

Dr. Thomas Tombler, chief executive officer, NanoPin Technologies, said, "The current diagnostic solutions available for the detection and monitoring of infectious disease are not sufficient because they limit patient outcomes and the global management of such ailments. Through our agreement with Thermo Fisher, our unique diagnostic platform has the potential to change how infectious diseases, such as tuberculosis, are detected, treated and controlled by solving the unmet needs of healthcare providers managing patient care throughout the world."


Source: Thermo Fisher Scientific

14.02.2020

Read all latest stories

Related articles

Photo

Addressing a broad range of research applications

Mass spectrometry advances

Since the Covid-19 epidemic took hold, the public has expected ‘unprecedented progress from the scientific community,’ observed Dan Shine, senior vice president and president of the analytical…

Photo

Liquid chromatography/mass spectrometry

LC-MS: Calling for easy-to-use platforms

Liquid chromatography/mass spectrometry (LC-MS) is an established powerful tool in routine clinical use and clinical research. However, to further capitalise on its benefits, instrument and…

Photo

Testing technology

Vitamin D testing: LC-MS outperforms immunoassays

In recent years, clinicians have increasingly focused on vitamin D deficiency. Studies show that previous reference values – particularly for Vitamin D3 – were most probably set too high. Liquid…

Related products

Beckman Coulter – DxONE Command Central Workstation

LIS, Middleware, POCT

Beckman Coulter – DxONE Command Central Workstation

Beckman Coulter, Inc.
Image Information Systems – iQ-4VIEW

Mobile RIS/PACS Viewer

Image Information Systems – iQ-4VIEW

IMAGE Information Systems Europe GmbH
i-Solutions Health – LabCentre

LIS, Middleware, POCT

i-Solutions Health – LabCentre

i-SOLUTIONS Health GmbH
Medat – Laboratory Information System

LIS, Middleware, POCT

Medat – Laboratory Information System

Medat Computer-Systeme GmbH
Mindray - CAL 8000 New Generation Cellular Analysis Line

Integrated Hematology

Mindray - CAL 8000 New Generation Cellular Analysis Line

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
Shimadzu – Axima iDplus Assurance

Mass Spectrometry

Shimadzu – Axima iDplus Assurance

Shimadzu Europa GmbH